Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Krystal Biotech, Inc. - Common Stock (NQ:KRYS)

265.22 -10.42 (-3.78%)
Streaming Delayed Price Updated: 12:12 PM EST, Mar 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Krystal Biotech, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million ↗
Nurix Therapeutics develops targeted cancer and immune disorder therapies, supported by partnerships with leading pharma companies. 
Via The Motley Fool
News headline image
Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120% ↗
This clinical-stage biotech develops antibody therapies for cancer and infectious diseases, leveraging proprietary discovery platforms. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year ↗
This clinical-stage biotech develops targeted cancer therapies, leveraging bispecific antibodies and strategic industry partnerships. 
Via The Motley Fool
Topics Regulatory Compliance
Krystal Biotech Inc (NASDAQ:KRYS) Reports Q4 2025 Earnings Beat and Key Pipeline Advancements ↗
Via Chartmill
Topics Earnings
News headline image
Earnings Scheduled For November 3, 2025 ↗
 
Via Benzinga
News headline image
Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025 ↗
Krystal Biotech develops redosable gene therapies targeting rare skin diseases, with a late-stage clinical pipeline and expanding portfolio. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26% ↗
Scholar Rock develops therapies for neuromuscular and oncological diseases, leveraging a proprietary platform to target unmet medical needs. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
KRYS Stock Rallies On Upbeat Earnings: Jefferies Ups Price Target On Sustained Vyjuvek Optimism ↗
Jefferies’ new price target represents a potential upside of about 34% from the stock’s closing price on Friday. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Krystal Biotech (KRYS) Q4 2025 Earnings Transcript ↗
Krystal Biotech (KRYS) Q4 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Got $300? 2 Biotech Stocks to Buy and Hold Forever ↗
These two biotechs only have one marketable therapy each, but both have blockbuster potential. 
Via The Motley Fool
News headline image
Soleus Adds a Significant Number of Celcuity Shares ↗
This clinical-stage biotech develops targeted cancer therapies and diagnostics using proprietary technology for personalized treatment. 
Via The Motley Fool
News headline image
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? ↗
This biopharma firm targets rare diseases with both approved therapies and a pipeline of clinical-stage treatments. 
Via The Motley Fool
News headline image
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? ↗
This biopharma firm targets rare diseases with both approved therapies and a pipeline of clinical-stage treatments. 
Via The Motley Fool
News headline image
Why a Fund Placed a $13 Million Bet on Ambarella Stock Before a 20% Post-Earnings Drop ↗
The timing looks painful, but the fundamentals tell a more complicated story about why long-term investors are still paying attention. 
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance
News headline image
Is IPG Photonics Stock a Buy as One Fund Builds a $9 Million Stake in the Firm? ↗
A sharp rebound in margins and profitability is testing whether patience can finally pay off for investors willing to look past years of volatility. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why One Fund Has an $8.5 Million Bet on Five9 Despite a 50% One-Year Stock Collapse ↗
The stock’s collapse tells one story, but the underlying business metrics suggest a very different long-term setup. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Up 44% Since IPO: Why a Major Fund Just Made a $45 Million Bet on This Digital Health Stock ↗
One fast-growing digital health stock just secured a notable new backer—right as its financial momentum hits a fresh gear. 
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound? ↗
One fund is quietly buying into ACADIA — just as the company posts one of its strongest quarters in years. 
Via The Motley Fool
News headline image
Soleno Turns First Profit on $66 Million in Revenue — Is This Why One Investor Just Made an $87 Million Bet? ↗
Soleno just turned profitable for the first time—right as a major fund made its move. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
$1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Healthcare Sector Navigates Turbulent Waters: Innovation Surges Amidst Political Headwinds
New York, NY – November 10, 2025 – The S&P 500 Healthcare sector presented a mixed picture today, with the broader index showing a modest uptick while significant segments, particularly health insurers... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
What's Driving the Market Sentiment Around Krystal Biotech Inc? ↗
 
Via Benzinga
News headline image
Krystal Biotech (KRYS) Q3 2025 Earnings Transcript ↗
Krystal Biotech (KRYS) Q3 2025 Earnings Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Krystal Biotech (KRYS) Q3 2025 Earnings Top Estimates on Strong VYJUVEK Sales ↗
Krystal Biotech's Q3 2025 earnings crushed estimates, with EPS of $2.66 and $97.8M revenue. Strong VYJUVEK sales and global expansion in Europe and Japan drive growth. 
Via Chartmill
News headline image
$1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Expert Outlook: Krystal Biotech Through The Eyes Of 9 Analysts ↗
 
Via Benzinga
News headline image
$100 Invested In Krystal Biotech 5 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Insider Confidence Shines: Krystal Biotech and Growth Stocks with Strong Management Stakes Navigate Volatile Markets
The U.S. stock market is currently a landscape of contrasting forces, with robust bank earnings providing a bedrock of stability against the backdrop of persistent trade tensions with China and... 
Via MarketMinute
Topics Artificial Intelligence World Trade
News headline image
What's Driving the Market Sentiment Around Krystal Biotech Inc? ↗
 
Via Benzinga
News headline image
6 Stocks Goldman Sachs Says Are Poised For Potential Acquisition In Next 12 Months — Including A Huge 200% Winner ↗
Goldman Sachs has highlighted six stocks that have a high probability of being acquisition targets in the next year. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.